Navigation Links
Angioplasty Not Always Worth the Price
Date:11/12/2008

Cost analysis finds procedure often doesn't bring enough benefit to offset expense

WEDNESDAY, Nov. 12 (HealthDay News) -- The high cost of angioplasty may not justify the marginal benefit, a new study suggests.

Researchers reporting at the American Heart Association's (AHA) annual scientific sessions in New Orleans found that adding angioplasty to optimal medical therapy improved angina-related symptoms in some patients but "at a cost generally considered to be prohibitive as a routine initial management strategy."

"This is an important trial," said Dr. Sidney Smith, chairman of the AHA/American College of Cardiology task force on guidelines. "More and more as we develop guidelines and treatment strategies for patients, the cost is important, and in this particular trial, it appeared the use of stents and additional angina associated with that was expensive."

But this doesn't mean the procedure shouldn't be performed.

"Cost should not be a total roadblock," Smith said. "It should be an incentive to do things in a better way, by targeting the population or making the procedure or drug in a less expensive way. . . . Let's find a way to fix the cost."

Currently, cost analyses of procedures and medications tend to lag behind studies of their effectiveness and place in the practice of medicine.

Prior research suggests that interventional procedures to re-open coronary arteries after blockages, when used with up-to-date medical therapy, does not actually reduce the incidence of cardiovascular events any more than medication alone.

The original trial, known as COURAGE, compared adding angioplasty to best medical therapy and lifestyle interventions to medical therapy alone in reducing the risk of dying or having a heart attack. It found little difference between the two.

According to the AHA, angioplasty involves inserting a thin tube from a groin artery to the blocked artery in the heart. Doctors then inflate a small balloon at the tip of the tube to widen the vessel, insert a stent and restore blood flow.

This secondary analysis involved 2,287 patients who were followed for a median of 4.6 years. Researchers compared the cost of treating angina in Canada, the U.S. non-VA health system and the U.S. VA health system.

Quality of life results were similar among groups, although physical limitation results did vary. The net benefit here ranged from less than 1 percent in U.S. non-VA hospitals to 18 percent in Canadian facilities.

When measured by the frequency of chest pain, researchers calculated the absolute net benefit to be 6.85 percent, with an average added cost for the PCI of $10,107 per patient.

The added cost of PCI ranged from a low of $5,906 per patient in Canada to a high of $15,896 in U.S. VA hospitals.

The overall cost per patient related to angina frequency (as assessed by a patient questionnaire) ranged from a low of $55,700 in Canada (the average in Canada was $118,740) to a high of more than $1 million at U.S. non-VA facilities. The analysis was done in 2004 U.S. dollars.

More information

The American Heart Association has more on angioplasty.



SOURCES: Sidney Smith, Jr., M.D., past president, American Heart Association, and professor, medicine, University of North Carolina, Chapel Hill; Nov. 12, 2008, presentation, American Heart Association annual scientific sessions, New Orleans


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hispanics less likely to have repeat revascularizations 1 year after angioplasty
2. Florida study finds barriers to angioplasty for life-threatening heart attacks
3. Angioplasty Scoring System Predicts Risk of Death
4. Angioplasty No Better Than Drug Treatment in Long Run
5. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
6. Off-Hours Heart Patients Less Likely to Get Angioplasty
7. State Report Ranks LIJ as New Yorks Best Hospital for Angioplasty Survival
8. Angioplasty Proves Reasonable Alternative to Bypass Surgery
9. Anticoagulant Drugs Had Similar Outcomes After Angioplasty
10. Comparison of anticoagulants for angioplasty show similar outcomes
11. The Elderly Can Be Candidates for Angioplasty, Stenting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Angioplasty Not Always Worth the Price
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology: